Pre-existing humoral immunity and CD4+T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination

被引：3
作者：
Shen, Ching-Fen [1 ,2 ]
Fu, Yi-Chen [3 ]
Ho, Tzong-Shiann [2 ,4 ,5 ]
Chen, Po-Lin [4 ]
Lee, Nan-Yao [6 ]
Tsai, Bo-Yang [7 ]
Tsai, Pei-Jane [7 ,8 ]
Ko, Wen-Chien [6 ]
Liu, Ching-Chuan [2 ,4 ]
Cheng, Chao-Min [3 ]
Shieh, Chi-Chang [1 ,2 ]
机构：
[1] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 70101, Taiwan
[2] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pediat, Tainan 70101, Taiwan
[3] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu 30013, Taiwan
[4] Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan 70101, Taiwan
[5] Tainan Hosp, Dept Pediat, Minist Hlth & Welf, Tainan 700007, Taiwan
[6] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan 70101, Taiwan
[7] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 70101, Taiwan
[8] Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Tainan 70101, Taiwan
来源：
CLINICAL IMMUNOLOGY | 2023年 / 251卷
关键词：
COVID-19; vaccines; Adenovirus vector vaccine; mRNA vaccine; Heterologous prime-boost immunization; Neutralizing antibody; T cell response; MATURATION; ANTIBODIES;
D O I：
10.1016/j.clim.2023.109342
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background: Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heter-ologous vaccination.Methods: We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-gamma release assay.Results: All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-gamma release by CD4+ T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender.Conclusions: A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4+ T cells response correlates with post-booster neutralization reactivity against the Omicron variant.
引用
收藏
页数：7
相关论文
共 40 条
  • [1] ACROBiosystems, 2022, ANTISARS COV 2 BA2 N
  • [2] Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
    Aiello, Alessandra
    Coppola, Andrea
    Vanini, Valentina
    Petrone, Linda
    Cuzzi, Gilda
    Salmi, Andrea
    Altera, Anna Maria Gerarda
    Tortorella, Carla
    Gualano, Gina
    Gasperini, Claudio
    Scolieri, Palma
    Beccacece, Alessia
    Vita, Serena
    Bruzzese, Vincenzo
    Lorenzetti, Roberto
    Palmieri, Fabrizio
    Nicastri, Emanuele
    Goletti, Delia
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 841 - 849
  • [3] SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection
    Altmann, Daniel M.
    Boyton, Rosemary J.
    [J]. SCIENCE IMMUNOLOGY, 2020, 5 (49)
  • [4] Contributions of humoral and cellular immunity to vaccine-induced protection in humans
    Amanna, Ian J.
    Slifka, Mark K.
    [J]. VIROLOGY, 2011, 411 (02) : 206 - 215
  • [5] Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
    Andrews, Nick
    Tessier, Elise
    Stowe, Julia
    Gower, Charlotte
    Kirsebom, Freja
    Simmons, Ruth
    Gallagher, Eileen
    Thelwall, Simon
    Groves, Natalie
    Dabrera, Gavin
    Myers, Richard
    Campbell, Colin N. J.
    Amirthalingam, Gayatri
    Edmunds, Matt
    Zambon, Maria
    Brown, Kevin
    Hopkins, Susan
    Chand, Meera
    Ladhani, Shamez N.
    Ramsay, Mary
    Bernal, Jamie Lopez
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04) : 340 - 350
  • [6] Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
    Assawakosri, Suvichada
    Kanokudom, Sitthichai
    Chansaenroj, Jira
    Suntronwong, Nungruthai
    Auphimai, Chompoonut
    Nilyanimit, Pornjarim
    Vichaiwattana, Preeyaporn
    Thongmee, Thanunrat
    Duangchinda, Thaneeya
    Chantima, Warangkana
    Pakchotanon, Pattarakul
    Srimuan, Donchida
    Thatsanatorn, Thaksaporn
    Klinfueng, Sirapa
    Sudhinaraset, Natthinee
    Mongkolsapaya, Juthathip
    Wanlapakorn, Nasamon
    Honsawek, Sittisak
    Poovorawan, Yong
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 793 - 801
  • [7] Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
    Barrett, Jordan R.
    Belij-Rammerstorfer, Sandra
    Dold, Christina
    Ewer, Katie J.
    Folegatti, Pedro M.
    Gilbride, Ciaran
    Halkerston, Rachel
    Hill, Jennifer
    Jenkin, Daniel
    Stockdale, Lisa
    Verheul, Marije K.
    Aley, Parvinder K.
    Angus, Brian
    Bellamy, Duncan
    Berrie, Eleanor
    Bibi, Sagida
    Bittaye, Mustapha
    Carroll, Miles W.
    Cavell, Breeze
    Clutterbuck, Elizabeth A.
    Edwards, Nick
    Flaxman, Amy
    Fuskova, Michelle
    Gorringe, Andrew
    Hallis, Bassam
    Kerridge, Simon
    Lawrie, Alison M.
    Linder, Aline
    Liu, Xinxue
    Madhavan, Meera
    Makinson, Rebecca
    Mellors, Jack
    Minassian, Angela
    Moore, Maria
    Mujadidi, Yama
    Plested, Emma
    Poulton, Ian
    Ramasamy, Maheshi N.
    Robinson, Hannah
    Rollier, Christine S.
    Song, Rinn
    Snape, Matthew D.
    Tarrant, Richard
    Taylor, Stephen
    Thomas, Kelly M.
    Voysey, Merryn
    Watson, Marion E. E.
    Wright, Daniel
    Douglas, Alexander D.
    Green, Catherine M.
    [J]. NATURE MEDICINE, 2021, 27 (02) : 279 - +
  • [8] Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination
    Bellusci, Lorenza
    Grubbs, Gabrielle
    Zahra, Fatema Tuz
    Forgacs, David
    Golding, Hana
    Ross, Ted M.
    Khurana, Surender
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [9] Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants
    Chiu, Chun-Hsiang
    Chang, Yu-Hsiu
    Tao, Chi-Wei
    Chang, Feng-Yee
    Chiu, Kuo-Chou
    Chang, Tien-Wei
    Yen, Li-Chen
    [J]. MICROBIOLOGY SPECTRUM, 2022, 10 (05):
  • [10] To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination
    Chiu, Nan-Chang
    Chi, Hsin
    Tu, Yu-Kang
    Huang, Ya-Ning
    Tai, Yu-Lin
    Weng, Shun-Long
    Chang, Lung
    Huang, Daniel Tsung-Ning
    Huang, Fu-Yuan
    Lin, Chien-Yu
    [J]. EXPERT REVIEW OF VACCINES, 2021, 20 (10) : 1211 - 1220
1234